Findings from Ghent University Update Understanding of Gene Therapy (Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication)
By a News Reporter-Staff News Editor at Cancer Vaccine Week -- A new study on Biotechnology is now available. According to news reporting originating in Ghent, Belgium, by NewsRx journalists, research stated, "In this work a combination therapy that acts upon the immune suppressive, the innate and specific arms of the immune system is proposed. This combination therapy, which consists of intratumoral interleukin-12 (IL-12) gene therapy, human tyrosinase (hTyr) DNA vaccination and metronomic cyclophosphamide (CPX), was evaluated in a B16-F10 mouse model."
The news reporters obtained a quote from the research from Ghent University, "The following groups were compared: (1) no treatment, (2) control vector, (3) intratumoral IL-12 gene therapy, (4) intratumoral IL-12 gene therapy + metronomic CPX, (5) intratumoral IL-12 gene therapy + metronomic CPX + hTyr DNA vaccination. Next to clinical efficacy and safety, we characterized acute effects of IL-12 and anti-tumor immune response after a second tumor challenge. All treatment groups showed increased survival and higher cure rates than control groups. Survival of non-cured mice was increased when metronomic CPX was combined with IL-12 gene therapy. Furthermore, mice that received metronomic CPX had significantly lower percentages of regulatory T cells. Addition of the hTyr DNA vaccine increased cure rate and resulted in increased survival compared to other treatment groups. We also demonstrated that the manifest necrosis within days after IL-12 gene therapy is at least partly due to IL-12 mediated activation of NK cells. All cured mice were resistant to a second challenge. A humoral memory response against the tumor cells was observed in all groups that received IL-12 gene therapy, while a cellular memory response was observed only in the vaccinated mice."
According to the news reporters, the research concluded: "Every component of this combination treatment contributed a unique immunologic trait with associated clinical benefits."
For more information on this research see: Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication. Journal of Controlled Release, 2014;187():175-182. Journal of Controlled Release can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)
Our news correspondents report that additional information may be obtained by contacting S. Denies, University of Ghent, Fac Med & Hlth Sci, Dept. of Biochem, B-9000 Ghent, Belgium. Additional authors for this research include L. Cicchelero, I. Van Audenhove and N.N. Sanders (see also Biotechnology).
Keywords for this news article include: Antineoplastics, Biotechnology, Pharmaceuticals, Ghent, Drugs, Europe, Belgium, Oncology, Cytokines, Immunology, Vaccination, DNA Research, Hydrocarbons, Immunization, Interleukins, Bioengineering, Cancer Vaccines, Cyclophosphamide, Alkylating Agents, Mustard Compounds, Cancer Gene Therapy, Phosphoramide Mustards
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC